Nemolizumab & Waxing: Estheticians’ 2026 Guide

A recent study published in the Journal of the American Academy of Dermatology indicated that nearly 70% of individuals with moderate-to-severe atopic dermatitis experience persistent itch even with conventional treatments, underscoring the significant unmet need for targeted therapies. This persistent itch dramatically impacts quality of life, often making routine skin care and even professional treatments like waxing a complex consideration for those with atopic skin. As an esthetician, understanding the nuances of emerging treatments like Nemolizumab is paramount for providing safe and effective care. How does this novel biologic impact our approach to skin health and hair removal?

The IL-31 Pathway: A Focused Approach to Itch Relief

Nemolizumab operates by selectively blocking the interleukin-31 (IL-31) receptor, a cytokine known to play a central role in the pathogenesis of itch and inflammation in atopic dermatitis. According to The New England Journal of Medicine, IL-31 levels are significantly elevated in the skin and serum of patients with atopic dermatitis, correlating directly with disease severity and the intensity of pruritus. This specific targeting is a significant departure from older systemic treatments that often suppress the immune system more broadly, leading to a wider range of potential side effects. My professional interpretation of this data is that Nemolizumab represents a more refined tool in managing atopic dermatitis, focusing on a primary driver of discomfort rather than a shotgun approach. For estheticians, this specificity implies that while the underlying condition remains, the skin’s immediate reactivity to external stimuli, particularly itch, might be considerably diminished. This doesn’t mean the skin is “cured” or suddenly strong, but rather that one of its most troublesome symptoms is under more precise control. This distinction is vital when considering any skin treatment.

Clinical Efficacy: Reducing Itch and Improving Skin Barrier

Phase 3 clinical trials, such as the OLYMPIA 2 study, have demonstrated Nemolizumab’s efficacy. A report from the American Academy of Dermatology highlighted that patients receiving Nemolizumab experienced a mean reduction of 43.7% in peak pruritus numerical rating scale (NRS) scores by week 16, compared to a mere 20.9% in the placebo group. Plus, significant improvements were observed in sleep disturbance and quality of life measures, secondary to the reduction in itch. For me, these numbers are not just statistics. They represent a tangible shift in how clients with atopic skin might present in the treatment room. A client whose chronic itch has been reduced by nearly half is likely to have skin that is less excoriated, less inflamed, and potentially more receptive to gentle hair removal techniques. This improvement in the skin barrier, while not directly measured as a primary endpoint in all Nemolizumab studies, is a natural consequence of less scratching and irritation. My experience suggests that a compromised skin barrier is a primary contraindication for waxing, so any treatment that helps restore its integrity is a positive development for estheticians. However, a less itchy client doesn’t mean a client without atopic dermatitis. The underlying predisposition to inflammation and sensitivity remains, requiring continued vigilance.

Potential Side Effects and Esthetician Considerations

While Nemolizumab is generally well-tolerated, clinical trials have reported some side effects, including injection site reactions, peripheral edema, and headache. The FDA’s review documents for Nemolizumab provide detailed safety profiles. The incidence of severe adverse events was low, but estheticians must be aware of these possibilities. For instance, peripheral edema, or swelling, could alter skin texture and make it more fragile or sensitive to pressure during waxing. Injection site reactions, though usually localized and transient, could be mistaken for other skin irritations if not properly identified in a client’s history. My professional opinion here is unwavering: a thorough consultation is non-negotiable. Asking about current medications, including biologics like Nemolizumab, and any associated side effects is critical. I’ve seen situations where clients, eager for hair removal, might downplay mild symptoms. It is our responsibility to probe gently but thoroughly. If a client reports recent peripheral edema, for example, even if mild, it warrants a more cautious approach to waxing, perhaps even postponing the service until the symptom resolves or consulting with their dermatologist.

Conventional Wisdom: Not All Atopic Skin is Equal

The conventional wisdom often dictates a blanket “no waxing” policy for individuals with severe atopic dermatitis, and for good reason. Historically, the compromised skin barrier, extreme sensitivity, and risk of exacerbating inflammation made waxing a high-risk proposition. However, with targeted therapies like Nemolizumab, this blanket rule requires re-evaluation. I disagree with the notion that all atopic skin, regardless of treatment or current condition, is automatically unsuitable for professional hair removal. The data on Nemolizumab’s ability to significantly reduce itch and inflammation suggests a sea change. While the skin still carries the diagnosis of atopic dermatitis, its functional state under effective treatment can be deeply different from untreated, severely inflamed skin. This isn’t to say that waxing becomes universally safe or advisable, but rather that a nuanced, individualized assessment is now more critical than ever. We must move beyond generalizations and focus on the client’s current skin presentation, their treatment regimen, and their dermatologist’s recommendations. An esthetician’s expertise in skin assessment, combined with an understanding of these new treatments, allows for a more informed decision-making process. This might involve patch testing with a very gentle hard wax in an inconspicuous area, or opting for alternative hair removal methods if any doubt remains.

Best Practices for Waxing Clients on Nemolizumab

When a client on Nemolizumab presents for waxing, several best practices become paramount. Firstly, detailed client intake forms must specifically inquire about prescription medications, including biologics, and any ongoing dermatological conditions. Secondly, always request a signed waiver acknowledging the client’s skin condition and their understanding of potential risks associated with waxing, even with their current treatment. Thirdly, prioritize gentle, low-temperature hard wax. Hard wax adheres only to the hair, not the skin, minimizing trauma. Avoid strip wax entirely, as its pulling action can be too aggressive for sensitive or compromised skin. Fourthly, perform a patch test. Apply a small amount of wax to a discrete area, like the inner arm or thigh, and observe for 24-48 hours for any adverse reactions. This step is non-negotiable. Finally, educate the client on careful aftercare, emphasizing soothing, fragrance-free products and avoiding harsh exfoliants. The goal is always to minimize irritation and support the skin barrier. Remember, our role is to enhance skin health, not inadvertently trigger a flare-up. If there’s any uncertainty, refer the client back to their dermatologist for clearance.

The advent of targeted therapies like Nemolizumab is transforming the field of atopic dermatitis management, offering significant relief from debilitating itch. For estheticians, this means a more hopeful outlook for clients with atopic skin, allowing for careful consideration of professional treatments that were once largely contraindicated. Always prioritize thorough consultation, careful technique, and ongoing communication with healthcare providers to ensure the safest and most effective care for these clients. For more insights on managing post-wax skin, consider reading about post-wax aftercare myths debunked and essential secrets for flawless skin.